Platelet Function Monitoring in Patients With Acute Myocardial Infarction
This study is being done to learn more about platelet reactivity (how well the small cells in the bloodstream work) in people who undergo Percutaneous coronary intervention (PCI) for stable and unstable (acute myocardial infarction) indications. Stable means you have not demonstrated any acute injury to your heart prior to your PCI; unstable means you have demonstrated some acute injury to your heart prior to your PCI. The investigators intend to determine if there is a change in platelet reactivity from the time of PCI to 30days post-PCI and does this change differ depending upon the conduction in which you present for PCI. This is going to be done with a variety of platelet reactivity assays.
Acute Myocardial Infarction
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Platelet Function Monitoring in Patients With Acute Myocardial Infarction|
- Platelet function [ Time Frame: 30 days ] [ Designated as safety issue: No ]The primary endpoint will be whether the results of platelet function assays used to measure response to clopidogrel and prasugrel therapy is similar amongst patients with stable CAD and those with AMI undergoing PCI. On-treatment platelet reactivity will be measured using the VerifyNow P2Y12 assay.
- On-treatment platelet reactivity [ Time Frame: 30 days ] [ Designated as safety issue: No ]
A secondary endpoint will be to determine on-treatment platelet reactivity at the same time points using:
- The vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay; and/or
- The Chrono-Log Lumi-Aggregometer, which measures platelet aggregation (via optical density or electrical impedance) in response to ADP stimulation.
|Study Start Date:||December 2010|
|Study Completion Date:||September 2013|
|Primary Completion Date:||September 2013 (Final data collection date for primary outcome measure)|
Patients with stable CAD undergoing PCI
AMI Cases treated with clopidogrel
Patient with AMI undergoing PCI
AMI Cases treated with prasugrel
Patients with AMI undergoing PCI
Please refer to this study by its ClinicalTrials.gov identifier: NCT01353261
|United States, District of Columbia|
|Washington Hospital Center|
|Washington, District of Columbia, United States, 20010|
|Principal Investigator:||Ron Waksman, MD||Washington Hospital Center|